Seqirus UK Limited
Records under this name other than the patents Seqirus UK Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 57 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,655,108 | Cell-Derived Viral Vaccines with Low Levels of Residual Cell DNA Formerly held In force · High confidence | In force | High confidence | |
| US 9,708,585 | Influenza Virus Reassortment Formerly held In force · High confidence | In force | High confidence | |
| US 10,500,266 | Influenza Virus Reassortment Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 10,232,031 | Influenza Virus Reassortment Formerly held In force · High confidence | In force | High confidence | |
| US 10,329,537 | Influenza Virus Reassortment Formerly held In force · High confidence | In force | High confidence | |
| US 10,842,867 | Adjuvanted Vaccines with Non-Virion Antigens Prepared from Influenza Viruses Grown in Cell Culture Term ended Term ended Nov 6, 2026 · High confidence | Term ended | Term ended Nov 6, 2026 | High confidence |
| US 11,466,257 | Cell-Derived Viral Vaccines with Low Levels of Residual Cell DNA Term ended Term ended Nov 1, 2026 · High confidence | Term ended | Term ended Nov 1, 2026 | High confidence |
| US 10,030,231 | Influenza Virus Reassortment Formerly held Lapsed on the fee record Ended Jul 24, 2026 · High confidence | Lapsed on the fee record | Ended Jul 24, 2026 | High confidence |
| US 10,112,979 | Influenza vaccination Term ended Term ended Nov 3, 2025 · From the USPTO record | Term ended | Term ended Nov 3, 2025 | From the USPTO record |
| US 10,329,536 | Methods for producing an active constituent of a pharmaceutical or a diagnostic agent in an mdck cell suspension culture Term ended Term ended Mar 7, 2023 · High confidence | Term ended | Term ended Mar 7, 2023 | High confidence |